Aprepitant [Emend], given in combination with conventional antiemetic therapy, is more effective than the established regimen alone in preventing chemotherapy-induced nausea and vomiting, according to a study presented at the European Society of Medical Oncology (ESMO) meeting [Vienna, Austria; October−November 2004]. In a large study involving patients receiving moderately emetogenic chemotherapy (MEC) for breast cancer, the addition of aprepitant enhanced the efficacy of a regimen comprising ondansetron plus dexamethasone. Furthermore, the benefits observed with aprepitant were maintained over multiple treatment cycles."These are exciting results... Reducing chemotherapy induced nausea and vomiting, and the associated distress and disruption to daily activities, remains an important target for therapeutic intervention,"commented Dr Carsten Bokemeyer from the University of Tübingen, Germany.